About UW Medicine Anticoagulation Services

This website contains UWMedicine recommendations, guidelines and protocols for the treatment and prevention of venous and arterial thrombosis, and the clinical use of antithrombotic agents in ambulatory and inpatient settings.

UWMedicine Anticoagulation Services is operated by the UWMedicine Department of Pharmacy, and collaborates with multidisciplinary specialties and providers  across UWMedicine to develop and disseminate guidelines and to coordinate the use of antithrombotic agents across the UWMedicine enterprise.  

UWMedicine Anticoagulation Services also provides management of anticoagulant therapy in pharmacist-managed anticoagulation clinics at the University of Washington Medical Center (UWMC) , Seattle Cancer Care Alliance (SCCA) and Harborview Medical Center (HMC).  Pharmacist providers in these clinics are involved in clinical practice, training and education, and research activities consistent with the mission of UW Medicine and the Department of Pharmacy.

"The goals of pharmacist-managed anticoagulation services include treatment and prevention of thromboembolic disease and minimization of complications of antithrombotic therapy."

Use the links to the left to navigate through the major sections of this site. The links at the top are the most frequently visited areas. BY USING THE SITE, YOU AGREE TO THE TERMS OF USE; IF YOU DO NOT AGREE, DO NOT USE THE SITE.

 

 

REVISED GUIDELINES - Recommendations for Chronic Antithrombotic Therapy

In March 2017, the American Heart Association/American College of Cardiology Task Force on Clinical Practice Guidelines published a focused update to the AHA/ACC guideline for management of patients with valvular heart disease. The UWMedicine Recommendations for Chronic Antithrombotic Therapy have been revised to reflect this focused update.

REVISED GUIDELINES - Guidelines for Reversing Coagulopathies in Patients with Symptomatic Spontaneous Intraparenchymal Hemorrhage

In February 2017, UWMedicine Guidelines for Reverse Coagulopathies in Patients with Symptomatic Intraparenchymal Hemorrhage and related algorithms were revised to reflect the availability of idarucizumab for reversal of dabigatran, edoxaban (a new factor Xa inhibitor) and the PATCH trial (Lancet 2016; 387:2605-13) investigating the role of platelet transfusion in IPH patients taking antiplatelet agents. 

REVISED GUIDELINES - Risk Stratification and Recommendations for Bridge Therapy in Patients on Warfarin

In January 2017, the American College of Cardiology published new recommendations for periprocedural management of anticoagulation in patients with nonvalvular AF.  These guidelines use the CHA2DS2-VASc score, rather than the CHADS2 score, to guide decision-making.  As a result, UWMedicine's Risk Stratification and Recommendations for Bridge Therapy in Patients on Warfarin has been revised.  

NEW - Patient Information on Bridging

In December 2016, two new patient education handouts were developed. Inpatient Bridging for Patients on Warfarin and Outpatient Bridging for Patients on Warfarin can be cound in the Patient Education tab above. 

REVISED GUIDELINES - Mechanical Circulatory Support Anticoagulation Guidelines

In December 2016, the Mechanical Circulatory Support Anticoagulation Guidelines were revised. The update is posted on the MCS Website and on the UWMedicine Anticoagulation Services website.

REVISED GUIDELINES - VTE Prophylaxis Guidelines by Clinical Group

In November 2016, UWMedicine VTE Prophylaxis Guidelines by Clinical Group were revised to reflect changes in practice related to Harborview Medical Center trauma patients (trauma, acute spinal cord injury and spine fracture repair, regardless of covering service).

REVISED GUIDELINES - Recommendations for Chronic Antithrombotic Therapy

In September 2016, a revision to UWMedicine Recommendations for Chronic Antithrombotic Therapy was posted, to highlight updates  in guidelines from various sources.

REVISED GUIDELINES - Neuraxial Procedures and Anticoagulation

In March 2016, the UWMedicine guidelines on Management of Antithrombotic Therapy for Neuraxial Procedures were revised by the Dept of Anesthesia and Pain Medicine, the Dept of Pharmacy, and UWMedicine Anticoagulation Services. Please find the revised guidelines in the section titled Peri-Procedural Anticoagulation Management.

NEW GUIDELINES - Perioperative Management of Antiplatelet Therapy

In March 2016, new UWMedicine guidelines for Perioperative Management of Antiplatelet Therapy in Patients Undergoing Non-Cardiac Surgery/Procedures were approved. The link to these guidelines can be found in the section titled Peri-Procedural Anticoagulation

Pages